Therefore, the MMP7 inhibitor EGCG was used to treat 17 RDEB patients in an RCT-clinical trial with the aim to reduce blister numbers as well as itch, and to improve wound healing. The gene discussed is MMP7; the disease is recessive dystrophic epidermolysis bullosa.